Innovus announced that the Food and Drug Administration (FDA) has granted clearance for UriVarx urinary tract infection (UTI) test strips for use in patients with overactive bladder (OAB) and urinary incontinence (UI). 

UriVarx UTI test strips detect the presence of leukocytes and nitrites to help screen for UTI during self-testing; results can be seen in 2 minutes.The new test strips are complementary to the UriVarx supplements (proprietary blend of lindera extract, horsetail extract, Cratevox three-lead caper extract) that are already available. The supplements are intended to reduce urinary urgency, accidents, and day/night frequency in patients with OAB and UI.

UriVarx UTI test strips are anticipated to launch this quarter and will be available over-the-counter (OTC).

Continue Reading

Related Articles


Innovus Pharma announces US Food and Drug Administration clearance of its UriVarx urinary tract infection test strips [press release]. San Diego, CA; Business Wire: January 11, 2018. Accessed January 17, 2018,

This article originally appeared on MPR